BioSpace News Archive

Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.

G1 Therapeutics, Inc., a commercial-stage oncology company, provided a corporate and financial update for the third quarter ended September 30, 2021.

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, November 10, 2021 to report its third quarter 2021 financial results and provide a corporate update.

GRO Biosciences Inc. today announced the closing of a Series A financing totaling $25 million co-led by Leaps by Bayer and Redmile Group.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will be participating in the following upcoming investor conferences:

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced that it will host a key opinion leader roundtable discussion on the ReSPECT-GBM trial on Thursday, November 18, 2021, 4:00 to 5:00 p.m. ET.

Harvard Bioscience, Inc. announced financial results for the period ended September 30, 2021.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in November.

Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2021.

Clade Therapeutics today announced it has secured an $87 million Series A financing led by Syncona Ltd. with participation from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb.